Evidence map›Paper›PMID 28687934›Full record

Trial reportEuropean journal of nutrition2018

Co-administration of a konjac-based fibre blend and American ginseng (Panax quinquefolius L.) on glycaemic control and serum lipids in type 2 diabetes: a randomized controlled, cross-over clinical trial.

Alexandra L Jenkins, Linda M Morgan, Jacqueline Bishop, Elena Jovanovski, David J A Jenkins, Vladimir Vuksan

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nutrition, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02806349 (Effect of Co-administration of a Konjac-Glucomannan Fibre Blend and American Ginseng), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02806349 phase2completednot on this map

Effect of Co-administration of a Konjac-Glucomannan Fibre Blend and American Ginseng (Panax Quinquefolius L.) on Glycemia and Serum Lipids in Well-controlled Type 2 Diabetes: A Randomized Controlled, Clinical Trial

TypeinterventionalSponsorVladimir VuksanRan2002 to 2005Enrolled39ConditionsDiabetes Mellitus, Type 2ArmsAmerican Ginseng, Konjac-glucomannan fiber blend, Control
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review of Ginseng Anti-Diabetic Studies.Molecules (Basel, Switzerland) · 2019
    Review
  10. American Ginseng (Nutrients · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Alexandra L JenkinsClinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.ORCID http://orcid.org/0000-0002-0921-4553
Linda M MorganDepartment of Nutritional Sciences, School of Biosciences and Medicine, University of Surrey, Guildford, UK.
Jacqueline BishopDepartment of Nutritional Sciences, School of Biosciences and Medicine, University of Surrey, Guildford, UK.
Elena JovanovskiClinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.
David J A JenkinsClinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.
Vladimir VuksanClinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada. v.vuksan@utoronto.ca.
St. Michael's Hospital · CAUniversity of Surrey · GB

Funding

Diabetes Canada 1125
6 · The paper itself

Abstract

purposeUse of polypharmacy in the treatment of diabetes is the norm; nonetheless, optimal control is often not achieved. Konjac-glucomannan-based fibre blend (KGB) and American ginseng (AG) have individually been shown to improve glycaemia and CVD risk factors in type 2 diabetes. The aim of this study was to determine whether co-administration of KGB and AG could improve diabetes control beyond conventional treatment.

methodThirty-nine participants with type 2 diabetes (6.5 > A1c < 8.4%) were enrolled between January 2002 and May 2003 at the Risk Factor Modification Centre at St Michaels Hospital in a randomized, placebo-controlled, crossover trial with each intervention lasting 12-weeks. Medications, diet and lifestyle were kept constant. Interventions consisted of 6 g of fibre from KGB together with 3 g of AG (KGB and AG) or wheat bran-based, fibre-matched control. Primary endpoint was the difference in HbA1c levels at week 12.

resultsThirty participants (18M:12F; age: 64 ± 7 years; BMI: 28 ± 5 kg/m

conclusionsCo-administration of KGB and AG increases the effectiveness of conventional therapy through a moderate but clinically meaningful reduction in HbA1c and lipid concentrations over 12 weeks in patients with type 2 diabetes. CLINICAL TRIALS REGISTRATION: NCT02806349 ( https://clinicaltrials.gov/ ).

Indexed as

AmorphophallusPanaxAdultAgedBlood GlucoseCanadaCross-Over StudiesDiabetes Mellitus, Type 2FemaleGlycemic IndexHumansLipid MetabolismLipidsMaleMiddle AgedPlant ExtractsBlood GlucoseLipidsPlant ExtractsAmerican ginsengDietary fibreGlucomannanKonjac mannanType 2 diabetesXanthan

Identifiers

PMID28687934
OpenAlexW2726355349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.